Table 1 Clinical trials with BTK inhibitors in B cell malignancies
From: Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Patient population | Therapeutic regimen | Phase | Efficacy | Ref |
|---|---|---|---|---|
R/R CLL | Ibrutinib | Ib/II | ORR (71%), PR (20%) | [11] |
R/R CLL | Ibrutinib | III | ORR (63%) | [248] |
TN CLL | Ibrutinib | Ib/II | ORR (85%), CR (26%) | [199] |
TN CLL | Ibrutinib | III | ORR (86%), CR (4%) | [13] |
R/R MCL | Ibrutinib | II | ORR (68%), CR (21%) | [187] |
R/R MCL | Ibrutinib | III | ORR (72%), CR (19%) | [249] |
R/R WM | Ibrutinib | II | ORR (91%), Major response (73%) | [188] |
R/R ABC-DLBCL | Ibrutinib | II | ORR (37%) | [196] |
R/R CLL | Ibrutinib-Rituximab | II | ORR (95%), CR (8%) | [250] |
R/R CLL | Ibrutinib-bendamustine-rituximab | III | ORR (83%), CR (10%) | [251] |
R/R MCL | Ibrutinib-Rituximab | II | ORR (88%), CR (44%), PR (44%) | [252] |
R/R CLL | Acalabrutinib | I/II | ORR (95%) | [12] |
R/R | Acalabrutinib | II | ORR (81%), CR (40%), PR (41%) | [219] |
R/R CLL | ONO/GS-4059 | I | ORR (96%) | [222] |
R/R MCL | ONO/GS-4059 | I | ORR (92%) | [222] |
R/R non-GCB DLBCL | ONO/GS-4059 | I | ORR (35%) | [222] |
R/R CLL | BGB-3111 | I | ORR (90%) | [221, 253] |
R/R MCL | BGB-3111 | I | ORR (80%) | [253] |
R/R MZL | Ibrutinib | II | ORR (51%) | [254] |
R/R FL | Ibrutinib | I | ORR (38%) | [186] |